PCSK9 and acute coronary syndrome: Adding proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to moderate- or high-intensity statin therapy regimens leads to cardiovascular risk reduction in patients with stable atherosclerotic cardiovascular disease, or after recent acute coronary syndromes [14,15].